Chapter 1 ā What the Illuminator Does
Section 1.5 ā Notes to Transfusionists
1-7
Section 1.5 Notes to Transfusionists
While laboratory studies of amotosalen processing with UVA light have shown a
reduction in levels of certain viruses and bacteria, there is no pathogen
inactivation process that has been shown to eliminate all pathogens.
INTERCEPT platelets or plasma components should not be prescribed to
neonatal patients treated with phototherapy devices that emit a peak energy
wavelength less than 425 nm, and/or have a lower bound of the emission
bandwidth <375 nm, due to the risk of erythema resulting from potential
interaction between ultraviolet light (below 400 nm) and residual amotosalen.
To Next Page
Loading...